Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C

Journal of Hepatology

Volumn 56, Issue 3, 2012, Pages 602-608

  Kurosaki, Masayuki ^a   Hiramatsu, Naoki ^b   Sakamoto, Minoru ^c   Suzuki, Yoshiyuki ^d   Iwasaki, Manabu ^e   Tamori, Akihiro ^f   Matsuura, Kentaro ^g   Kakinuma, Sei ^h   Sugauchi, Fuminaka ⁱ   Sakamoto, Naoya ^h   Nakagawa, Mina ^h   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e SEIKEI UNIVERSITY   (Japan)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^h TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

ⁱ National Hospital Organization   (Japan)

Author keywords

Decision tree; Pegylated interferon; Prediction; Ribavirin; Risk

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CANCER RISK; CHRONIC HEPATITIS; CONTROLLED STUDY; DATA ANALYSIS; DATA MINING; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; REPRODUCIBILITY; RISK ASSESSMENT; THROMBOCYTE;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DATA MINING; DECISION TREES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; POLYETHYLENE GLYCOLS; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS;

EID: 84857373119     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.09.011     Document Type: Article

References (37)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. F.X. Bosch, J. Ribes, M. Diaz, and R. Cleries Primary liver cancer: worldwide incidence and trends Gastroenterology 127 2004 S5 S16
3. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
4. G. Fattovich, G. Giustina, F. Degos, F. Tremolada, G. Diodati, and P. Almasio Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
5. C. Niederau, S. Lange, T. Heintges, A. Erhardt, M. Buschkamp, and D. Hurter Prognosis of chronic hepatitis C: results of a large, prospective cohort study Hepatology 28 1998 1687 1695
6. F. Degos, C. Christidis, N. Ganne-Carrie, J.P. Farmachidi, C. Degott, and C. Guettier Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death Gut 47 2000 131 136
7. H. Yoshida, R. Tateishi, Y. Arakawa, M. Sata, S. Fujiyama, and S. Nishiguchi Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C Gut 53 2004 425 430
8. M. Kurosaki, T. Hosokawa, K. Matsunaga, I. Hirayama, T. Tanaka, and M. Sato Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy Hepatol Res 40 2010 870 877
9. R.F. Velazquez, M. Rodriguez, C.A. Navascues, A. Linares, R. Perez, and N.G. Sotorrios Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis Hepatology 37 2003 520 527
10. A.S. Lok, L.B. Seeff, T.R. Morgan, A.M. di Bisceglie, R.K. Sterling, and T.M. Curto Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease Gastroenterology 136 2009 138 148
11. A.C. Cardoso, R. Moucari, C. Figueiredo-Mendes, M.P. Ripault, N. Giuily, and C. Castelnau Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis J Hepatol 52 2010 652 657
12. A. Craxi, and C. Camma Prevention of hepatocellular carcinoma Clin Liver Dis 9 2005 329 346 viii
13. L.J.H. Breiman, R.A. Friedman, C.J. Olshen, and C.M. Stone Classification and regression trees 1980 Wadsworth Calif
14. M. Garzotto, Y. Park, S. Mongoue-Tchokote, J. Bledsoe, L. Peters, and B.H. Blank Recursive partitioning for risk stratification in men undergoing repeat prostate biopsies Cancer 104 2005 1911 1917
15. K. Miyaki, I. Takei, K. Watanabe, H. Nakashima, and K. Omae Novel statistical classification model of type 2 diabetes mellitus patients for tailor-made prevention using data mining algorithm J Epidemiol 12 2002 243 248
16. B.J. Averbook, P. Fu, J.S. Rao, and E.G. Mansour A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: implications on the future of cancer staging Surgery 132 2002 589 602
17. U. Leiter, P.G. Buettner, T.K. Eigentler, and C. Garbe Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society J Clin Oncol 22 2004 3660 3667
18. V.A. Valera, B.A. Walter, N. Yokoyama, Y. Koyama, T. Iiai, and H. Okamoto Prognostic groups in colorectal carcinoma patients based on tumor cell proliferation and classification and regression tree (CART) survival analysis Ann Surg Oncol 14 2007 34 40
19. I. Zlobec, R. Steele, N. Nigam, and C.C. Compton A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods Clin Cancer Res 11 2005 5440 5443
20. A. Baquerizo, D. Anselmo, C. Shackleton, T.W. Chen, C. Cao, and M. Weaver Phosphorus as an early predictive factor in patients with acute liver failure Transplantation 75 2003 2007 2014
21. M. Kurosaki, K. Matsunaga, I. Hirayama, T. Tanaka, M. Sato, and Y. Yasui A predictive model of response to peginterferon ribavirin in chronic hepatitis c using classification and regression tree analysis Hepatol Res 40 2010 251 260
22. M. Kurosaki, N. Sakamoto, M. Iwasaki, M. Sakamoto, Y. Suzuki, and N. Hiramatsu Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis J Med Virol 83 2011 445 452
23. N. Izumi, Y. Asahina, and M. Kurosaki Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors Hepat Res Treat 2010 2010 703602
24. M. Kurosaki, N. Sakamoto, M. Iwasaki, M. Sakamoto, Y. Suzuki, and N. Hiramatsu Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis J Gastroenterol 46 2011 401 409
25. M. Kurosaki, Y. Tanaka, N. Nishida, N. Sakamoto, N. Enomoto, and M. Honda Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors J Hepatol 54 2011 439 448
26. Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, et al. Age and total ribavirin dose is an independent predictor of relapse among early virological responders to peg-interferon plus ribavirin therapy in chronic hepatitis C revealed by data mining analysis. Antivir Ther, in press.
27. N. Hiramatsu, M. Kurosaki, N. Sakamoto, M. Iwasaki, M. Sakamoto, and Y. Suzuki Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis J Gastroenterol 46 2011 1111 1119
28. M. LeBlanc, and J. Crowley A review of tree-based prognostic models Cancer Treat Res 75 1995 113 124
29. S.N. Lu, J.H. Wang, S.L. Liu, C.H. Hung, C.H. Chen, and H.D. Tung Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma Cancer 107 2006 2212 2222
30. S. Bruno, T. Stroffolini, M. Colombo, S. Bollani, L. Benvegnu, and G. Mazzella Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study Hepatology 45 2007 579 587
31. P.A. Bonis, M.J. Tong, L.M. Blatt, A. Conrad, and J.L. Griffith A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C Am J Gastroenterol 94 1999 1605 1612
32. Y. Asahina, K. Tsuchiya, N. Tamaki, I. Hirayama, T. Tanaka, and M. Sato Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection Hepatology 52 2010 518 527
33. N. Ganne-Carrie, C. Chastang, F. Chapel, C. Munz, D. Pateron, and M. Sibony Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis Hepatology 23 1996 1112 1118
34. S. Nishiguchi, T. Kuroki, S. Nakatani, H. Morimoto, T. Takeda, and S. Nakajima Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1995 1051 1055
35. Y. Shiratori, Y. Ito, O. Yokosuka, F. Imazeki, R. Nakata, and N. Tanaka Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival Ann Intern Med 142 2005 105 114
36. C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, and T. Goeser Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
37. J.G. McHutchison, G.T. Everson, S.C. Gordon, I.M. Jacobson, M. Sulkowski, and R. Kauffman Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838